Last reviewed: November 3, 2026
A Tavneos withdrawal headline can leave a family with the wrong date in mind. Australia’s announced date is March 31, 2027. Nothing in that notice gives an American patient until then to seek care for liver symptoms or to bring a legal claim.
We checked the October 16 notice from Australia’s Therapeutic Goods Administration (TGA) against the U.S. documents. Here is what each says. Our Tavneos lawsuit hub covers the underlying injury allegations.
In Australia, the sponsor has announced plans to withdraw
CSL Seqirus told the TGA it intends to withdraw Tavneos from the Australian Register of Therapeutic Goods. The agency describes March 31, 2027 as the expected effective date. Until then, there are different instructions for new patients and people already receiving the medicine.
Doctors should not start new patients on Tavneos, the notice says. Patients already taking it should discuss their options with their treating healthcare professional before stopping. For continued treatment or a transition to another therapy, the notice draws attention to known and potential risks, including liver injury and additional monitoring requirements.
Why was the TGA looking at Tavneos? Its August 3 announcement raised concerns about the integrity and reliability of the clinical trial data behind approval. That review was underway when the sponsor advised the agency of its withdrawal plans. The October notice does not give readers a final investigation report.
Australia’s date also differs from the timetable discussed in our coverage of the EU and UK actions. A withdrawal announcement needs a country attached to it.
In the United States, read the FDA proposal and Amgen’s response
FDA’s April 27 proposal says Tavneos has not been shown effective for its approved use and that its approval application contained untrue statements of material fact. Amgen disagrees with the proposed withdrawal. Its patient FAQ still says Tavneos is available in the United States when checked on November 3.
FDA explains that the drug remains on the market until the applicant removes it or the FDA Commissioner mandates removal. The TGA notice does not accomplish either step here. If a U.S. refill is your immediate concern, Amgen directs that question to your pharmacy or prescribing doctor.
For liver symptoms, do not wait for a market decision
There is another March 31 in this story: FDA issued its liver injury warning on March 31, 2026. That warning tells patients to contact a healthcare professional immediately for symptoms that may indicate liver injury. Among its examples are yellowing skin or eyes, unusual itching, dark urine and pain in the right upper abdomen.
Patients should discuss whether to continue Tavneos or switch treatments with their healthcare professional, FDA says. Australia’s future withdrawal date offers no reason to postpone that discussion.
For families considering a lawsuit, the Australian notice is a document about a market withdrawal, not an individual injury finding. It does not establish that Tavneos caused someone’s liver damage. Nor does it announce compensation or an American filing deadline. Ask a lawyer which deadline applies to your own circumstances; do not use March 2027 as a substitute for that advice.
Sources
- TGA withdrawal notice, October 16, 2026
- TGA review announcement, August 3, 2026
- FDA proposal to withdraw approval
- Amgen patient FAQ
- FDA liver injury warning, March 31, 2026
Attorney advertising. General information only, not medical or legal advice. Reading this article does not create an attorney-client relationship. Compensation and outcomes are not guaranteed. Discuss medication changes with your treating clinician.
Robert B. Baker, Esq., B.C.S. — Board-Certified Civil Trial Lawyer. 30+ years of trial experience, more than $400 million recovered for clients. About Robert Baker →
This website provides general information. Your circumstances require an individual review.